RARE News and Press, Ultragenyx Pharmaceutical Inc. From 12/31/22

Summary GLPG is setting to transform its business after a slew of failures. The new CEO is a global expert at this, and I don't see him failing. They have a huge cash stockpile. I haven’t covered Galapagos ( GLPG ) in a while. My last coverage of t...

Get ahead of the market by subscribing to Seeking Alpha's Stocks to Watch, a preview of key events scheduled for the coming week. The newsletter keeps you informed of the biggest stories set to make headlines, including upcoming IPOs, investor days, earnings reports and conference presentations. ...

NOVATO, Calif., Nov. 22, 2022 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for serious rare and ultra-rare genetic diseases, today announced that Emil D. Kakkis, M.D., Ph.D....

Ultragenyx Pharmaceutical ( NASDAQ: RARE ) said Thursday its CFO Mardi Dier will step down , effective Nov. 15, to assume the dual role of CFO and chief business development officer at private biopharmaceutical firm ACELYRIN. Ultragenyx ( RARE ) said Ted Huizenga, chie...

NOVATO, Calif., Nov. 10, 2022 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) announced that Mardi Dier, Chief Financial Officer (CFO) and Executive Vice President, is leaving the company, effective November 15, 2022, to assume the dual role of CFO and Chief Business Devel...

Ultragenyx Pharmaceutical Inc. (RARE) Q3 2022 Earnings Conference Call November 02, 2022 05:00 PM ET Company Participants Joshua Higa - Head of Investor Relations Emil Kakkis - Founder, President and Chief Executive Officer Erik Harris - Executive Vice President ...

Ultragenyx Pharmaceutical press release ( NASDAQ: RARE ): Q3 GAAP EPS of -$3.50 misses by $1.66 . Revenue of $90.7M (+11.1% Y/Y) misses by $5M . As of September 30, 2022, cash, cash equivalents, and marketable debt securities were $996.2 million, which includes...

Third quarter 2022 total revenue of $90.7 million and Crysvita® revenue in Ultragenyx territories 1 of $64.5 million Reaffirm 2022 Crysvita revenue in Ultragenyx territories guidance of $250 million to $260 million and Dojolvi revenue of $55 million to $65 milli...

Summary Having suffered through a sharp decline in earnings multiples, SMID cap growth stocks held up well in a volatile quarter marked by a sharp upward ratcheting of interest rates. The Strategy underperformed its benchmark, primarily due to weakness among health care holdings t...

NOVATO, Calif., Oct. 27, 2022 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel products for serious rare and ultra-rare genetic diseases, today announced that it will host a conference ca...